Krakow, Poland – May 31, 2017 – Selvita, one of the largest drug discovery company in Europe, has generated a very strong revenue growth in the first quarter of 2017.
In Q1 2017 Selvita Group recognized total operating revenues (incl. grants) in the amount of PLN 26.8 MM, which means an increase of 99% comparing to Q1 2016 when the operating revenues amounted to PLN 13.5 MM.
In Q1 2017 revenues from sales and other operating revenues (excl. grants) amounted to PLN 24.0 MM, which indicates dynamics at the level of 109% compared to Q1 2016, in which revenues from sales and other operating revenues (excl. grants) amounted to PLN 11.5 MM. What is worth mentioning, is that Selvita Group has recorded an increase in Q1 sales revenue (excl. grants) in all of its segments of activity (y-o-y change):
- Revenues of the innovation segment rose very significantly by 321% (PLN 16.4 MM vs. PLN 3.9MM). High dynamics of sales and operating profit in the innovation segment of the Group in Q1 2017 is mainly a result of SEL24 program commercialization.
- Revenues of the services segment showed a solid increase of 28% (PLN 8.9 MM vs. PLN 7.0 MM).
- The bioinformatics segment has generated a 258% increase in revenues (PLN 1.9 MM vs. PLN 0.53 MM).
Revenues in subsidies increased by 44% (PLN 2.82 MM vs. PLN 1.96 MM).
Current results indicate clearly that the company is developing strong across all divisions, enjoying solid revenue growth.
The Group’s operating profit in Q1 2017 amounted to PLN 8.1 MM and increased by PLN 7.6 MM – which means growth of 13-times – in comparison to Q1 2016 when it amounted to PLN 0.58 MM.
Group’s net profit for Q1 2017 amounted to PLN 6.0 MM compared to PLN 0.62 MM net profit achieved in Q1 2016. This means net profitability (calculated as the net profit divided by total operating revenues) at a level of 22% which means increase of 17 p.p. in comparison to net profitability of Q1 2016.
The English version (Summary) of the Selvita Consolidated Quarterly Report for Q1 2017 is available at: https://selvita.com/investor-relations/stock-market-reports/. The full version (in Polish) is available at: https://selvita.com/pl/centrum-inwestora/raporty-gieldowe/